Circulatory collapse

Spiders, Snakes and Other Spooky Pet Poison Dangers

Retrieved on: 
Wednesday, October 12, 2022
Myalgia, Veterinarian, Spider, Cramp, Color, Latrodectus, Bleeding, Bird, Biting, Animal, Circulatory collapse, Family, Bitten, Diarrhea, Pharmacy, IV, Medicine, Mouth, Xylitol, Veterinary medicine, Google, Dog, PETS, Seizure, Blood pressure, Extrapyramidal system, Eye, DVM, Candy, Poisoning, Vomiting, Black widow, Cat, GiFT, Chocolate, Spider bite, Diazepam, Swelling, DABT, Snake, Poison, Wiley, Breathe Me, Noise, Obstruction, Stomach, Paralysis, Bruise, Methocarbamol, Death, Coffee, Spasm, Tremor, Human, Toxicology, Flaccid paralysis, Fireworks, Medical imaging, Halloween

MINNEAPOLIS, Oct. 12, 2022 /PRNewswire/ -- Halloween conjures up many images, including spiders, snakes, ghosts and, for many revelers, buckets of candy. Most pet lovers know not to give their animals chocolate, but spiders and snakes can also pose a real danger to pets. As families celebrate this frightening haunted holiday, the toxicology experts at Pet Poison Helpline want to warn pet lovers about other real scares like spiders and snakes that can seriously sicken or kill your pet in this month's installment of Toxin Tails.

Key Points: 
  • As families celebrate this frightening haunted holiday, the toxicology experts at Pet Poison Helpline want to warn pet lovers about other real scares like spiders and snakes that can seriously sicken or kill your pet in this month's installment of Toxin Tails.
  • Being a trusted source for pet toxicology advice, Pet Poison Helpline is highly recommended by human poison control centers and veterinary professionals.
  • Pet Poison Helpline created Toxin Tails to educate the veterinary community and pet lovers on the many types of poisoning dangers facing pets, both in and out of the home.
  • As the most cost-effective option for animal poison control care, Pet Poison Helpline's fee of $75 per incident includes follow-up consultations for the duration of the case.

DGAP-News: Dipeptidyl peptidase 3 biomarker to drive precision medicine in COVID-19

Retrieved on: 
Tuesday, April 12, 2022
Life, Biomarker, Safety, Death, Clinical trial, Mortality, Patient, II, Heart, COVID-19, Gesellschaft mit beschränkter Haftung, Survival, Multiple organ dysfunction syndrome, Cardiac output, COVID 19, Teaching hospital, Precision medicine, Angiotensin, Hemodynamics, CEO, Jean-Louis Vincent, Medicine, DPP3, Critical care, Intensive Care Medicine (journal), Medication, Septic shock, Cardiogenic shock, DOI, Circulatory collapse, COVID, Consequential damages, Blood, Tracheal collapse, Organ dysfunction, Pharmaceutical industry, Hospital, Medical device, Vaccine, Latins (Italic tribe), Sepsis, Dipeptidyl peptidase

The study will be using two biomarkers, bioactive adrenomedullin (bio-ADM) and dipeptidyl peptidase 3 (DPP3), for patient stratification and inclusion criteria for the use of Adrecizumab (1).

Key Points: 
  • The study will be using two biomarkers, bioactive adrenomedullin (bio-ADM) and dipeptidyl peptidase 3 (DPP3), for patient stratification and inclusion criteria for the use of Adrecizumab (1).
  • This revolutionary approach could serve as a precision medicine strategy in patients with severe COVID 19 infection.
  • Both clinical pathways can be detected by specific biomarkers, bioactive Adrenomedullin (bio-ADM) for the loss of endothelial function and Dipeptidyl peptidase (DPP3) for the loss of heart function.
  • Med., DOI: doi.org/10.1111/joim.13220
    Magliocca, A.; Omland, T.; Latini, R. Dipeptidyl peptidase 3, a biomarker in cardiogenic shock and hopefully much more.

DGAP-News: The Biomarkers bio-ADM and DPP3 Complement Post-Cardiac Surgery Diagnostics to Early Detect Organ Failure

Retrieved on: 
Friday, April 1, 2022
Nexus, Risk, Biomarker, Radboud University Medical Center, Manifest and latent functions and dysfunctions, TSH, Cell death, Diagnosis, IVD, PCT, Hennigsdorf, CEO, Hemodynamics, N-terminal prohormone of brain natriuretic peptide, Cardiopulmonary bypass, DPP3, Critical care, Sepsis, Inflammation, Soft tissue injury, CA, Anesthesiology, Circulatory collapse, ICU, Blood, Organ dysfunction, Patient, Dentistry, Hospital, Silviculture, Troponin

Bio-ADM may help identify patients with an increased risk of developing prolonged vasopressor dependence and prolonged ICU stay after cardiac surgery.

Key Points: 
  • Bio-ADM may help identify patients with an increased risk of developing prolonged vasopressor dependence and prolonged ICU stay after cardiac surgery.
  • Scientists from the Radboud University Medical Center have analyzed the predictive value of bio-ADM and DPP3 for short-term outcomes in a prospective study in cardiac surgery patients.
  • Compromised hemodynamics after surgery triggers the release of the hormone bio-ADM, a key regulator of endothelial barrier function and vascular tone.
  • Not surgery-induced and persistently high concentration of DPP3 signals impaired tissue perfusion and high risk for organ failure (5).

Global Home Health Hubs Market to Reach $2.4 Billion by 2026

Retrieved on: 
Friday, March 11, 2022
Shift, GIA, SAN, POC, Internet, HHH, Accident, Adoption, Home, Depression, Health, Huber loss, Vyttila Mobility Hub, Philips, IOT, Product-service system, Degenerative disease, Growth, Adult, Marketing, Hospital, LLC, Diabetes, Home automation, Long-term care, Live, Kidney, Patient, Cloud computing, Arrhythmia, Awareness, Thyroid, Hypertension, Cambridge Consultants, AMC, Research, Circulatory collapse, Syncope, Emotional and behavioral disorders, Solution, Cisco Systems, Childhood chronic pain, Smartphone, Investment, Nursing home, Forecasting, Players, Automation, COVID-19, CAGR, Intelligence, Moyamoya disease, Medical device, Pet, Payment

SAN FRANCISCO, March 11, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Home Health Hubs - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, March 11, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Home Health Hubs - Global Market Trajectory & Analytics" .
  • Amid the COVID-19 crisis, the global market for Home Health Hubs estimated at US$751.1 Million in the year 2022, is projected to reach a revised size of US$2.4 Billion by 2026, growing at a CAGR of 35.8% over the analysis period.
  • This segment currently accounts for a 22.5% share of the global Home Health Hubs market.
  • Global Industry Analysts, Inc., ( www.strategyr.com ) is a renowned market research publisher the world`s only influencer driven market research company.

4TEEN4 Pharmaceuticals Selects AGC Biologics to Manufacture Procizumab

Retrieved on: 
Wednesday, December 1, 2021
Patient, Heart, Jean-Louis Vincent, Gesellschaft mit beschränkter Haftung, CEO, Septic shock, Partnership, DPP3, Critical care, Plasmid, Survival, DNA, GLOBE, Circulatory collapse, Contract, CDMO, Multiple organ dysfunction syndrome, Specialization, Degenerative disease, AGC, Fine chemical, Pharmaceutical industry, Vaccine

Seattle, Dec. 01, 2021 (GLOBE NEWSWIRE) -- AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with 4TEEN4 Pharmaceuticals GmbH (4TEEN4) to manufacture and commercialize Procizumab.

Key Points: 
  • Seattle, Dec. 01, 2021 (GLOBE NEWSWIRE) -- AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with 4TEEN4 Pharmaceuticals GmbH (4TEEN4) to manufacture and commercialize Procizumab.
  • The first-in-class monoclonal antibody Procizumab offers a new approach for the treatment of life-threatening diseases related to acute circulatory failure.
  • We look forward to partnering with 4TEEN4 and working together to develop and manufacture this revolutionary treatment, and help it reach the critical clinical trial phase, said Patricio Massera, Chief Executive Officer at AGC Biologics.
  • 4TEEN4 Pharmaceuticals GmbH (4TEEN4) was established in 2013 in Hennigsdorf near Berlin, Germany, by Dr. Andreas Bergmann, CEO of 4TEEN4, as part of his Medicine4Future Initiative.